Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hyphens Pharma International Ltd. ( (SG:1J5) ) has provided an announcement.
Hyphens Pharma International Limited has secured exclusive rights to commercialize the Metoject® subcutaneous autoinjector pen in Singapore, Malaysia, the Philippines, and Vietnam. This product, which administers methotrexate for rheumatoid arthritis and plaque psoriasis, is already established in over 15 countries, ensuring high bioavailability and reduced gastrointestinal side effects compared to oral administration. This strategic move is expected to enhance Hyphens Pharma’s market presence in the region and potentially improve treatment outcomes for patients.
More about Hyphens Pharma International Ltd.
Hyphens Pharma International Limited is Singapore’s leading specialty pharmaceutical and consumer healthcare group. The company focuses on marketing and distributing pharmaceutical products and healthcare solutions across various markets.
YTD Price Performance: 1.79%
Average Trading Volume: 57,120
Technical Sentiment Consensus Rating: Sell
Current Market Cap: S$88.12M
See more data about 1J5 stock on TipRanks’ Stock Analysis page.